• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Puma Biotechnology Inc filed SEC Form 8-K: Leadership Update

    5/9/25 8:57:31 AM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBYI alert in real time by email
    pbyi20250507_8k.htm
    false 0001401667 0001401667 2025-05-08 2025-05-08
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): May 8, 2025
     
    PUMA BIOTECHNOLOGY, INC.
    (Exact Name of Registrant as Specified in its Charter)
     
    Delaware
     
    001-35703
     
    77-0683487
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)
     
     
    10880 Wilshire Boulevard, Suite 2150
    Los Angeles, California 90024
    (Address of principal executive offices) (Zip Code)
     
    (424) 248-6500
    (Registrant’s telephone number, including area code)
     
    N/A
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading
    symbol
     
    Name of each exchange
    on which registered
    Common Stock, par value $0.0001 per share
     
    PBYI
     
    The Nasdaq Stock Market LLC
    (Nasdaq Global Select Market)
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 5.02
    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    On May 8, 2025, Puma Biotechnology, Inc. (the “Company”) terminated Jeff J. Ludwig as an employee and as its Chief Commercial Officer. In connection with the termination, Mr. Ludwig may receive the severance set forth in his employment offer letter provided he executes a general release of all claims against the Company within 60 days.
     
    The Company currently does not intend to name a new Chief Commercial Officer and will integrate the responsibilities previously held by Mr. Ludwig into the functions of the Company’s existing sales and marketing personnel.
     
     

     
     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
     
    PUMA BIOTECHNOLOGY, INC.
     
           
    Date: May 9, 2025
    By:
    /s/ Alan H. Auerbach
     
       
    Alan H. Auerbach
     
       
    Chief Executive Officer and President
     
     
     
     
    Get the next $PBYI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBYI

    DatePrice TargetRatingAnalyst
    9/28/2021$11.00Neutral → Buy
    Citigroup
    9/28/2021Neutral → Buy
    Citigroup
    8/6/2021$13.00 → $6.00Sector Perform
    RBC Capital
    8/6/2021$9.00 → $8.00Sell
    Goldman Sachs
    More analyst ratings

    $PBYI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Puma Biotechnology Reports First Quarter Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20

      5/8/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, April 1, 2025 a

      5/6/25 5:15:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

      ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ:PBYI) to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia. NERLYNX is designed to block human epidermal growth factor receptor 2 (HER2) in order to treat and limit breast cancer metastasis. Under the agreement, Er-Kim is appointed as the distribution partner for NERLYNX in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, and Uzb

      4/30/25 6:00:00 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    SEC Filings

    See more
    • Puma Biotechnology Inc filed SEC Form 8-K: Leadership Update

      8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/9/25 8:57:31 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Puma Biotechnology Inc

      10-Q - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/8/25 4:41:37 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/8/25 4:20:43 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Nougues Maximo F was granted 61,456 shares, increasing direct ownership by 40% to 213,751 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      2/11/25 6:58:40 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Ludwig Jeffrey Jerome was granted 47,841 shares, increasing direct ownership by 44% to 156,792 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      2/11/25 6:55:59 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Hunt Douglas M was granted 48,117 shares, increasing direct ownership by 39% to 172,711 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      2/11/25 6:53:52 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Puma Biotechnology Inc

      SC 13G - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

      3/29/24 10:40:57 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)

      SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

      2/14/24 8:19:11 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)

      SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

      2/13/24 5:12:15 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Puma Biotech. upgraded by Citigroup with a new price target

      Citigroup upgraded Puma Biotech. from Neutral to Buy and set a new price target of $11.00

      9/28/21 7:42:41 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology upgraded by Citigroup

      Citigroup upgraded Puma Biotechnology from Neutral to Buy

      9/28/21 4:54:51 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Puma Biotechnology with a new price target

      RBC Capital reiterated coverage of Puma Biotechnology with a rating of Sector Perform and set a new price target of $6.00 from $13.00 previously

      8/6/21 10:44:06 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Financials

    Live finance-specific insights

    See more
    • Puma Biotechnology Reports First Quarter Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20

      5/8/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 8, 2025, following the release of its first quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of

      4/24/25 4:11:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Based on accounting principles generally accepted in the United Stat

      2/27/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Leadership Updates

    Live Leadership Updates

    See more
    • Puma Biotechnology to Join Russell 3000 Index

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24. "We are very pleased to be included in the widely referenced Russell Indexes," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We believe that inclusion in the Russell 3000 will benefit our stockholders by increasing liquidity and providing exposure to a broader base of institutional investor

      5/28/24 9:00:00 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

      Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and

      11/17/22 4:15:00 PM ET
      $EPIX
      $PBYI
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff

      Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022. Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding oper

      8/15/22 5:00:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care